Godavari Biorefineries Ltd

Godavari Biorefineries Earnings Call Transcript: Key Takeaways

Q2 revenue rose 27.5% to ₹549.2 Cr and net loss narrowed to ₹15.2 Cr. Chemicals drove gains; sugar-ethanol remains loss-making and seasonal.

Godavari Biorefineries Investor Presentation: Key Takeaways

Q2 FY27 consolidated revenue ₹549.2 Cr (+27% YoY) and EBITDA ₹10.9 Cr (2.0% margin) turned positive; PAT loss ₹15.2 Cr. Bio-based chemicals drive growth; sugar/ethanol remains loss-making.

Godavari Biorefineries Results Update

Q2 FY27 revenue rose 26.6% YoY to Rs.549.8 Crore, with EBITDA turning positive. Net loss narrowed to Rs.15.2 Crore from Rs.41.6 Crore a year earlier.

Godavari Biorefineries Q2 FY27 Results: Net Loss of ₹15.2 Cr, Loss Narrows

Godavari Biorefineries Ltd reported revenue from operations of ₹549.2 Cr (+27.5% YoY) and a net loss of ₹15.2 Cr for Q2 FY27.

Key figure

Net loss ₹15.2 Cr

Godavari Biorefineries Board Meeting Date

Godavari Biorefineries has given prior intimation of a board meeting on 4 November 2026 to approve unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. The trading window stays closed from 1 October until 48 hours after results.

Godavari Biorefineries Other Announcement

Godavari Biorefineries Ltd has submitted its quarterly shareholding pattern as per SEBI regulations. This is a routine regulatory compliance filing.

Godavari Biorefineries Patent

Godavari Biorefineries Ltd has been granted a US patent for a compound targeting cancer treatment. This patent covers a novel class of cancer-inhibiting compounds.